Survival rates of dogs with lymphoma multiplied by 5,6
May 2019. Urodelia, a French research company focused on the development of a therapeutic cancer vaccine, and a team of Italian veterinary researchers publish promising results issued of 6 years of treatment of 300 dogs that show a survival rate compared to conventional chemotherapy that can be multiplied by 5.6 on targeted diseases.
Urodelia, AT THE HEART OF RESEARCH ON THERAPEUTIC VACCINES IN IMMUNO-ONCOLOGY
February 2019. Urodelia, a French research company focused on the development of a therapeutic vaccine in
oncology, is seeking to raise 2.5 million euros in 2019 to deploy its technology in veterinary
oncology and fund human health research. Its needs 6 million euros over 3 years.
A new therapeutic approach against dog B lymphoma
Italy, 2014. Press release in French and Italian